Loading...
Clinical potential of lurasidone in the management of schizophrenia
Lurasidone is a new second-generation antipsychotic approved in October 2010 by the Food and Drug Administration for the treatment of schizophrenia. Like other second-generation antipsychotics, lurasidone is a powerful antagonist of D(2) dopamine and 5HT(2A) serotonin receptors, but differs from the...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3132094/ https://ncbi.nlm.nih.gov/pubmed/21753886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S12701 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|